



Date: 16 January 2026

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E) Mumbai – 400051
Security Code: 540596	Security Code: ERIS

SUBJECT: INTIMATION UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 - ALLOTMENT OF 23,06,372 EQUITY SHARES OF ERIS LIFESCIENCES LIMITED (“COMPANY”) IN RELATION TO PREFERENTIAL ISSUE

This is in furtherance to the Board Meeting held on November 24, 2025, and the outcome thereof, as and the subsequent approval granted by the shareholders of the Company, obtained through postal ballot, on December 24, 2025 and our earlier intimation to the stock exchanges in connection thereof, for the issuance of equity shares on a preferential basis for consideration other than cash, in accordance with the applicable provisions of the Companies Act, 2013 (“**Act**”), and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“**SEBI ICDR Regulations**”) and other applicable laws.

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI LODR Regulations**”), we wish to bring to your notice that the Executive Committee of the Board of the Directors of the Company at its meeting held today i.e., January 16, 2026 has approved the allotment of 23,06,372 (Twenty-Three Lakh Six Thousand Three Hundred and Seventy-Two) fully paid-up equity shares of face value of Re. 1 (Indian Rupee One) each (“**Subscription Shares**”) at an issue price of INR 1835.35 (Indian Rupees One Thousand Eight Hundred and Thirty-Five and Thirty-Five Paise) per equity share, including a premium of INR 1834.35 (Indian Rupees One Thousand Eight Hundred and Thirty-Four and Thirty-Five Paise) on preferential basis through private placement to Mr. Naishadh Shah pursuant to the provisions of Section 42, 62 and other applicable provisions of the Act and the SEBI ICDR Regulations, for consideration other than cash i.e., in lieu of acquisition of 16,74,493 (Sixteen Lakh Seventy-Four Thousand Four Hundred and Ninety-Three) fully paid-up equity shares having a face value of INR 10 (Indian Rupees Ten) each (“**Sale Shares**”) of Swiss Parenterals Limited (“**Swiss**”) held by him (representing 30% of the total share capital of Swiss), which acquisition was completed by the Company on January 16, 2026. As a result of the acquisition of the Sale Shares, Swiss has become a wholly owned subsidiary of the Company.

In line with the Regulation 28(1) of SEBI LODR Regulations, the Company has received in-principal approval from the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) *vide* their letters dated January 9, 2026, in relation to the issue of the aforesaid equity shares on a preferential basis. The Subscription Shares shall rank pari-passu, in all respects, with the existing equity shares of the Company, other than the lock-in and/or transfer restrictions under SEBI ICDR Regulations and/or as set forth in the definitive agreements executed amongst the parties.

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



Consequent to the aforesaid allotment of the Subscription Shares, the paid-up equity capital of the Company has increased from INR 13,62,16,891 (Thirteen Crores Sixty Two Lakhs Sixteen Thousand Eight Hundred and Ninety One Rupees) consisting of 13,62,16,891 (Thirteen Crores Sixty Two Lakhs Sixteen Thousand Eight Hundred and Ninety One) equity shares of Re. 1 (Rupee One) each to INR 13,85,23,263/- (Thirteen Crores Eighty Five Lakhs Twenty Three Thousand Two Hundred and Sixty Three Indian Rupees) consisting of 13,85,23,263 (Thirteen Crores Eighty Five Lakhs Twenty Three Thousand Two Hundred and Sixty Three) equity shares.

The aforesaid Subscription Shares shall be listed on the NSE and BSE, upon receipt of the relevant listing approvals. Further, the Subscription Shares shall be locked in as specified under Chapter V of the SEBI ICDR Regulations.

This intimation shall be made available on the Company's website. This is for your information and records.

You are requested to kindly take the same on record.

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer
ICSI Mem. No: A26493

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867